Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.
about
An instrumental variable analysis of the impact of practice guidelines on improving quality of care and diabetes-related outcomes in the elderly Medicare populationRosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells.Activation of PPARs α, β/δ, and γ Impairs TGF-β1-Induced Collagens' Production and Modulates the TIMP-1/MMPs Balance in Three-Dimensional Cultured Chondrocytes.Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality.hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists.Pioglitazone attenuates vascular fibrosis in spontaneously hypertensive ratsThe Role of PPARs in Lung Fibrosis.Emerging drugs for diabetic nephropathy.Peroxisome proliferator-activated receptors in lung cancer.Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblastsDrug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?Combined Effects of PPAR γ Agonists and Epidermal Growth Factor Receptor Inhibitors in Human Proximal Tubule Cells.Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats.Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblastsMicroRNA-27a Induces Mesangial Cell Injury by Targeting of PPARγ, and its In Vivo Knockdown Prevents Progression of Diabetic NephropathyTelmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.PPARs and the kidney in metabolic syndrome.Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus.Peroxisome proliferator-activated receptor activating hypoglycemic effect of Gardenia jasminoides Ellis aqueous extract and improvement of insulin sensitivity in steroid induced insulin resistant rats.DHEA and frontal fibrosing alopecia: molecular and physiopathological mechanisms.Renal tubular epithelium-targeted peroxisome proliferator-activated receptor-γ maintains the epithelial phenotype and antagonizes renal fibrogenesis.PPARγ and chronic kidney disease.The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's DiseaseRenal epidermal growth factor receptor: its role in sodium and water homeostasis in diabetic nephropathy.Peroxisome proliferator activating receptor-γ and the podocyte.Comparative RNA-Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease.Troglitazone induces extracellular matrix and cytoskeleton remodeling in mouse collecting duct cells.Pioglitazone inhibits TGFβ induced keratocyte transformation to myofibroblast and extracellular matrix production.Rosiglitazone inhibits proliferation of renal proximal tubular cells via down-regulation of ERK and Akt.Antifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblasts.Relaxin signaling activates peroxisome proliferator-activated receptor gamma.Peroxisome proliferator-activated receptor gamma interacts with CIITA x RFX5 complex to repress type I collagen gene expression.Troglitazone and pioglitazone interactions via PPAR-gamma-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines.Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1.PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis.Peroxisome proliferator-activated receptor gamma agonist reduces the severity of post-ERCP pancreatitis in rats.Thiazolidinediones alter growth and epithelial cell integrity, independent of PPAR-γ and MAPK activation, in mouse M1 cortical collecting duct cells.Role of the EGF receptor in PPARγ-mediated sodium and water transport in human proximal tubule cells.
P2860
Q23922089-43282B22-9081-435D-BD20-E7DDDE95BEA0Q29347056-B8E15DAB-3473-4901-8A5D-25FBD07852A6Q34210856-4AB3079C-1578-4A55-ACC3-462BD8567BC0Q35629015-40E93537-660F-411F-A520-177175FB6249Q35677086-4F626D4B-BFC6-47B5-B916-31874821C9A4Q35884929-5A4E0653-CB03-40BE-8FF0-A38241A3C305Q35925362-90AEB22A-99AB-4111-BBFD-12241FA7A345Q36302838-AC50F3D0-C309-48E3-A799-C5634B30FDB3Q36417658-89B2726A-6B6A-40E2-BFAC-B182DDB9F507Q36417662-A6134A35-9859-4B12-8C2E-7D7C10B2845FQ36577073-21F3ECF6-03F5-413F-BFD6-99CC00389CEDQ36591722-0289BECB-F615-4B0F-AA2B-513B9D5BEDF0Q36682692-D88BF04A-3BE0-4F0E-966C-7619D3249760Q36731626-75CFEE55-2647-402F-9C33-CA7EDF70F395Q36734442-1CCE64C4-BF11-4D33-A659-6B712D1BC09DQ36906818-A6D9C8A5-F404-4A1E-8F93-917AFFE435E7Q37041284-8C271233-025E-4D8D-9320-B2E25962EEBDQ37042128-019AC2D6-DE8E-4954-B5C0-2039EAA558D1Q37072216-77ACC89C-9209-4546-8AF9-3445AE69458BQ37306331-218C68B0-BBCA-44F6-B8E0-EA6EE68F2234Q37501666-68C75B6C-D0EB-429E-B5BA-246B49EFC055Q37540435-9E16B4BD-FBC8-4754-BE73-A2AED70FC94EQ37662113-A199B388-B99B-461F-9A78-89552014A41DQ37777055-F25A8A69-241B-440B-9479-261A974DD875Q37781280-3A3ED331-4405-4A63-8D60-0C746C1A3E77Q37820693-442669BF-0AFE-4CF7-9454-1615A2AEF0C3Q38815188-26470288-423B-47F7-B485-7761CA72F4B4Q38921141-7516C914-68AF-4BDF-A016-F2C1A8E0DC07Q39364983-15EC0E0C-D8BE-439B-B712-C5DA44439BBEQ39624471-19B0CC2F-E049-4F23-AE8A-BB1F4BAC6BFFQ39746277-DB1FFDF6-D90F-4D4B-B02A-39D6B905E431Q39771067-EBB62FA0-9FE9-4CEE-93F4-B092588854F4Q39807254-6C829020-6B11-41F7-A404-FBC6575D0E05Q40111521-A558906C-8A90-4AF2-8A14-6D3BC42283B5Q40215655-B287E8AB-59B3-4BF4-8461-64763D38C288Q40419035-F28B7CFB-8965-425A-B9F7-C76C7C27FB9AQ41879222-8FDB473B-EA75-4EF7-BF21-FFC62595AF84Q41952635-6F6E7698-5373-4434-AD81-3135871F0C2CQ43158772-E4AF750F-2D6E-4A69-AC75-CE1B3D3620B6Q44720793-1CB118F7-3DE1-4975-96F3-572FE4CC79F3
P2860
Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Pioglitazone inhibits cell gro ...... n in human kidney fibroblasts.
@en
Pioglitazone inhibits cell gro ...... n in human kidney fibroblasts.
@nl
type
label
Pioglitazone inhibits cell gro ...... n in human kidney fibroblasts.
@en
Pioglitazone inhibits cell gro ...... n in human kidney fibroblasts.
@nl
prefLabel
Pioglitazone inhibits cell gro ...... n in human kidney fibroblasts.
@en
Pioglitazone inhibits cell gro ...... n in human kidney fibroblasts.
@nl
P2093
P356
P1476
Pioglitazone inhibits cell gro ...... on in human kidney fibroblasts
@en
P2093
Carol A Pollock
Scott R Stanners
Sonia Saad
Stephen Zafiriou
Tania S Polhill
P304
P356
10.1681/ASN.2004040278
P577
2005-02-02T00:00:00Z